Treating recalcitrant verruca vulgaris in a pediatric patient with H2 blocker: An easy alternative approach  by Wu, Ching-Ying & Chang, Chung-Hsing
Journal of the Formosan Medical Association (2016) 115, 380e381Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.jfma-onl ine.comCORRESPONDENCETreating recalcitrant verruca vulgaris in a
pediatric patient with H2 blocker: An easy
alternative approach
Ching-Ying Wu a,b, Chung-Hsing Chang b,c,*a Department of Dermatology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan
b Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
c College of Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanReceived 10 March 2015; received in revised form 16 June 2015; accepted 23 June 2015A 7-year-old girl had a recalcitrant hyperkeratotic plaque
on her left index finger, which had been present since the
age of 3. She was referred to us for further management.
During the past 4 years, she had received multiple sessions
of liquid nitrogen treatment at monthly intervals. Because
of intense pain and easy blistering after repeated cryo-
therapies, topical applications of Duofilm liquid (3% sali-
cylic acid) and Aldara cream (5% imiquimod) were
introduced; however, the verrucous plaque slightly
reduced in size but regrew easily. Upon applying heavy
pressure to the lesion site, hemorrhagic blisters frequently
occurred.
At her initial presentation, there were multiple
brownish, verrucous papules aggregated on the coarse,
indurated plaque on her left index finger (Figure 1A),
indicating the typical appearance of verruca vulgaris. To
identify the possible immunocompromised condition for
this intractable lesion, common blood counts, immuno-
globulin (Ig) G, IgM, and IgE were measured. These levels
were all within normal limits, except for IgA, which was
decreased (63.5 mg/dL; normal range 82e453 mg/dL). No
signs of erosion or bone invasion were observed on an X-rayConflicts of interest: The authors have no conflicts of interest
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with oral ranitidine (150 mg/d) for 4 weeks. Four weeks
later, the verrucous plaque disappeared dramatically
without any scar (Figure 1B).
Cutaneous verruca occurs most commonly in children
and young adults. It is also most commonly reported in
hospital staff and vendors of meat and seafood. For those
with more extensive or recalcitrant lesions, a predisposing
condition such as atopic dermatitis or decreased cell-
mediated immunity is usually found.1 The major treat-
ment strategies are aimed at tissue destruction, with the
goal of destroying the virus-containing epidermis and pre-
serving as much uninvolved tissue as possible. In clinical
practice, cryotherapy is a simple practice and has long
been the first-line standard treatment for dermatologists or
physicians; however, when heavy pressure was applied to
the lesion site, hemorrhagic blisters frequently occurred
and caused intensive pain in our case.
Newer concepts for human papillomavirus treatment
now focus on enhancing innate immunity. In our case, the
patient responded well to ranitidine, a histamine-2 recep-
tor antagonist. The proposed mechanisms underlying the
immunomodulatory effects of a H2 blocker are inhibition of
suppressor T-lymphocyte activity, an increase in
interleukin-2 production, and an enhancement of natural
killer-cell activity. A few side effects include dizziness,
somnolence, arrhythmias, and skin rashes, which are dose
related and mainly confined to elderly patients. Results of
uncontrolled studies suggest that cimetidine therapyby Elsevier Taiwan LLC. This is an open access article under the
4.0/).
Figure 1 (A) Grouped verrucous papules on the tip of the left index finger. (B) Fingertip after treatment.
Treating recalcitrant verruca vulgaris 381(30e50 mg/kg/d up to 3 months) may be effective.2,3 By
contrast, other placebo-controlled, double-blind studies
reported that cimetidine therapy for adults was not much
more effective than placebo,4 but a trend toward efficacy
was suggested for younger patients.5 A third double-blind
study found that cimetidine combined with levamisole
caused regression of severe recalcitrant warts in 18 of 21
(86%) treated patients. In this case, we used ranitidine
(6 mg/kg/d) for 4 weeks and achieved complete remission.
With this excellent result, we would like to highlight this
noninvasive, painless, and cost-effective way of using a H2
blocker as the primary choice of treatment. When
encountering recalcitrant warts in pediatric patients we
encourage using a H2 blocker, especially for cases treated
with liquid nitrogen for 2 months or over four sessions
without success.References
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